Multifaceted virus-like particles: Navigating towards broadly effective influenza A virus vaccines

Area of Science:

• Virology and Immunology
• Vaccine Technology Development

Background:

• Annual influenza A virus (IAV) infections cause significant mortality and morbidity globally.
• Current egg-based flu vaccines have limitations including production time, cost, moderate efficacy in the elderly, and lack of cross-protection.
• Need for improved vaccine strategies to address conserved IAV antigens and enhance immunogenicity.

Purpose of the Study:

• To review recent advancements in broadly effective IAV antigens and their display on virus-like particles (VLPs).
• To discuss current IAV VLP vaccine production systems and administration routes.
• To explore the potential of VLPs in overcoming current vaccine limitations and advancing intranasal vaccination.

Main Methods:

• Review of pre-clinical and clinical studies on IAV VLP vaccines.
• Analysis of strategies for displaying conserved IAV antigens on VLPs.
• Examination of VLP vaccine production systems and administration methods (intranasal, transdermal).

Main Results:

• VLPs can display multiple conserved IAV antigens, enhancing immune responses.
• Various production systems for IAV VLP vaccines are available and under development.
• Intranasal and transdermal administration routes show potential for VLP vaccines.

Conclusions:

• IAV VLP vaccines represent a promising strategy for developing broadly protective and rapidly produced influenza vaccines.
• VLPs offer advantages in overcoming immunological limitations and enabling novel administration routes like intranasal vaccination.
• Further clinical trials and expedited production are anticipated for the commercialization of IAV VLP vaccines.